Aethlon Medical, Inc. — FY2017 Form 10-K Summary
Business context and reporting period
This is an annual report for the fiscal year ended March 31, 2017 (filed June 28, 2017), rather than a standalone 2016 fourth-quarter report. Aethlon is a clinical-stage medical technology company developing the Hemopurifier, an extracorporeal device intended to capture viruses from blood, and owns 80% of Exosome Sciences, which is developing exosome-based diagnostic candidates. Neither business had commercial product revenue during the year.
The Hemopurifier remains investigational in the United States and is a Class III device expected to require FDA premarket approval for marketing. A U.S. FDA-approved feasibility study in HCV-infected dialysis patients treated eight patients; the filing reports no device-related adverse events among enrolled subjects and an average capture of 154 million HCV International Units during four-hour treatments. These results do not establish efficacy or commercial approval. ESI’s TauSome biomarker work includes plans for a study of up to 200 former professional football players.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $392,073 | $886,572 |
| Operating expenses | $6,490,430 | $5,271,406 |
| Operating loss | $6,098,357 | $4,384,834 |
| Net loss attributable to common stockholders | $7,276,113 | $4,872,329 |
| Basic and diluted loss per share | $0.94 | $0.66 |
| Net cash used in operating activities | $3,505,900 | $4,329,307 |
| Cash at year-end | $1,559,701 | $2,123,737 |
Revenue was entirely government-contract revenue, chiefly from DARPA, and fell about 56% year over year. The DARPA contract and Battelle subcontract are complete; the company reported no expected future revenue from the DARPA award. Operating expenses rose about 23%, largely reflecting higher stock-based compensation. The company recorded $2.19 million of stock-based compensation versus $203,000 in FY2016. Other expense was $1.21 million, including a $558,198 debt-extinguishment loss, $345,841 warrant-repricing expense and $304,330 of interest and other debt expense. These items contributed to the larger net loss. Product gross margin is not applicable to the reported revenue base.
At March 31, 2017, working capital was $985,496, total assets were $1.73 million and total liabilities were $1.13 million. Current liabilities were $611,756. Convertible notes had $1.29 million principal outstanding, reported at $519,200 net of $774,011 of unamortized discounts; accrued interest was $5,391. The notes generally bear 10% interest and are convertible, creating refinancing and dilution exposure. The company reported $2.96 million net cash provided by financing activities, including $2.76 million net proceeds from common-stock sales and $577,460 from convertible notes, partly offset by $378,518 in RSU tax-withholding payments. Cash declined by $564,036 during the year.
Material changes versus the prior year
- Revenue declined by $494,499 as the government-contract work wound down and the final DARPA milestones were invoiced.
- Net loss attributable to common stockholders increased by about $2.40 million. Operating expenses increased by $1.22 million, including a substantial rise in noncash stock-based compensation; debt and warrant modification charges also increased other expense.
- Cash used in operations improved by approximately $823,000, but year-end cash and working capital fell to $1.56 million and $985,496, respectively.
- The company raised capital through an at-the-market program and a March 2017 registered direct offering. The latter generated $1.80 million net proceeds and included warrants to purchase 575,000 shares. Further share issuance or note conversion could materially dilute existing holders.
Outlook, risks and unusual items
Management expects continuing losses and negative cash flows for the foreseeable future. It plans to fund FY2018 operations and clinical development through additional debt or equity financing and government grants. Management stated that cash on hand and anticipated financing should meet FY2018 liquidity needs, but the auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern. The filing says financing may not be available on acceptable terms, or at all, and that operations could cease without sufficient capital.
Management planned to submit an FDA Expedited Access Pathway application, including a request for Breakthrough Technology designation. Neither acceptance nor accelerated regulatory progress is assured. The company has no established sales or marketing capability, has limited staff, and relies substantially on third parties for development and manufacturing. Key risks include clinical or regulatory failure, inability to raise capital, competition, product-liability exposure and Nasdaq listing compliance. Nasdaq had notified the company of deficiencies relating to market value of listed securities and board/audit committee independence, with compliance deadlines described in the filing.
Other notable matters include the completion of the five-year DARPA contract in September 2016 and significant convertible-note and warrant amendments. In June 2017, after year-end, holders agreed to extend note maturities to July 2019 in exchange for reducing conversion prices to $3.00 per share. The auditor issued an unqualified opinion on the financial statements with a going-concern explanatory paragraph. Management reported disclosure controls and internal control over financial reporting as effective at year-end.
Most important facts for investors to verify
- Current cash runway, financing actually secured after the filing, and whether management’s FY2018 funding assumptions were met.
- Outstanding convertible-note principal, accrued interest, maturity and conversion terms, and the fully diluted share count after warrants, options and RSUs.
- Progress, enrollment, safety findings and FDA feedback for Hemopurifier studies; distinguish viral capture observations from demonstrated clinical benefit.
- Status and terms of any FDA pathway submission or designation, and the remaining clinical and regulatory requirements for marketing.
- Whether Nasdaq listing and board-independence deficiencies were resolved by the stated deadlines.
- How much future revenue, if any, can replace the completed DARPA and Battelle contracts; the filing reports no clear source of recurring commercial revenue.